Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of SELLAS Life Sciences Group's Galinpepimut-S?
Galinpepimut-S is a subunit vaccine commercialized by SELLAS Life Sciences Group, with a leading Phase III program in Acute Myelocytic...